Results 171 to 180 of about 52,444 (287)

Insulin Pumps for Individuals With Type 2 Diabetes. [PDF]

Diabetes Spectr
Brown S, Romeo GR, Toschi E.
europepmc   +1 more source

An Implantable Scaffold Sequentially Releasing STING Agonist and B7‐H3 Antibody for Bone Metastasis Immunotherapy

Advanced Science, EarlyView.
We developed an implantable dual‐drug depot using GelMA for bone metastasis treatment, co‐delivering MSA‐2 and αB7‐H3‐loaded CaCO3 microparticles. Sustained release from GelMA scaffold enables MSA‐2 to activate STING signaling and enhance T‐cell infiltration and activation, while sequentially released αB7‐H3 blocks MSA‐2‐induced B7‐H3 upregulation ...
Qijun Lin, Hong Xiao, Shuai Fan, Kaimin Cai, Yanteng Xu, Xinwen Wang, Guanhong Chen, Chuandong Lang, Xinsheng Peng, Mingqiang Li, Yuhu Dai   +10 more
wiley   +1 more source

Effectiveness of video consultations in type 1 diabetes patients treated with insulin pumps in the outpatient clinic: a randomised controlled trial. [PDF]

Diabetologia
Schultz ANØ, Christensen R, Bollig G, Kidholm K, Brandt F.   +4 more
europepmc   +1 more source

Targeting WTAP/ROR1/WNT5A‐Mediated Crosstalk Between Glioma Stem Cells and Macrophages to Normalize Tumor Vasculature and Enhance Chemotherapy

Advanced Science, EarlyView.
In hypoxic microenvironment, WNT5A is predominantly secreted by tumor‐associated macrophages. Hypoxia‐induced WTAP mediates ROR1 stability by m6A modifications in a HuR‐dependent manner in Glioma stem cells (GSCs). WNT5A activates the WNT pathway via ROR1 binding on GSCs, driving glioma‐derived endothelial cells (GDECs) differentiation.
Xiaoyong Chen, Bo Pang, Yun Liu, Jiangwei Wang, Lanhui Zheng, Yuzhou Chang, Yingxuan Sun, Haoyuan Sun, Huiyuan Chen, Jiawei Cai, Zanyi Wu, Qing Chang, Yongzhi Wang, Dezhi Kang, Tao Jiang, Ruichao Chai   +15 more
wiley   +1 more source

Comparison of Metabolic Control, Dietary Habits, Activity, and Psychological Condition in Children and Adolescents Treated with Personal Insulin Pumps. [PDF]

Nutrients
Lejk A, Myśliwiec K, Chrzanowski J, Burzyński J, Michalak A, Musiał-Paździor M, Bandura M, Rutkowska-Kośmińska J, Drzewińska K, Grabowska A, Okonek M, Herstowska M, Hoffmann M, Fendler W.   +13 more
europepmc   +1 more source

Patients with Type 1 Diabetes Treated with Insulin Pumps Need Widely Heterogeneous Basal Rate Profiles Ranging from Negligible to Pronounced Diurnal Variability. [PDF]

J Diabetes Sci Technol, 2021
Lindmeyer AM, Meier JJ, Nauck MA.
europepmc   +1 more source

Piperazine‐Functionalized Nanoparticles Enable Oral Insulin Delivery in Obese Mice

Advanced Science, EarlyView.
ABSTRACT Biologics have gained prominence as a rapidly advancing therapeutic modality for a diverse spectrum of medical conditions. Nonetheless, they are predominantly administered parenterally due to poor absorption through the gastrointestinal tract. Additionally, repeated injections of biologics such as insulin cause injection pain, leading to dose ...
Yuxue Cao, Xiaofan Jiang, Md Moniruzzaman, Alexandra Mueller, Taskeen Iqbal Janjua, Nisha Tyagi, Zhi Qu, Kuan Yau Wong, Yuran Feng, Aayushi Ghodasara, Ekaterina Strounina, Benjamin P. Ross, Tushar Kumeria, Sumaira Z. Hasnain, Amirali Popat   +14 more
wiley   +1 more source

Initiating Insulin Pumps in Youth with New-onset Type 1 Diabetes: A Quality Improvement Initiative. [PDF]

Pediatr Qual Saf
Vakharia M, Lyons SK, Buckingham D, Rittenhouse M, McKay S, Sonabend R, Kim G.   +6 more
europepmc   +1 more source

Diabetes and technology: A pilot study on the management of patients with insulin pumps during the COVID-19 pandemic. [PDF]

Diabetes Res Clin Pract, 2020
Petrelli F, Cangelosi G, Scuri S, Pantanetti P, Lavorgna F, Faldetta F, De Carolis C, Rocchi R, Debernardi G, Florescu A, Nittari G, Sagaro GG, Garda G, Nguyen CTT, Grappasonni I.   +14 more
europepmc   +1 more source

Dual Aptamers‐Based SETDB1 PROTACs as Effective Anti‐Tumor Strategies for Breast Cancer

Advanced Science, EarlyView.
This study establishes dual‐aptamer PROTACs targeting SETDB1 using a SETDB1‐specific aptamer conjugated to AS1411. The designed PROTACs penetrate cells, recruit MDM2 to degrade SETDB1, and inhibit cancer cell proliferation and migration. Remarkably, they also overcome tamoxifen resistance and enhance CD8+ T cell cytotoxicity, suppressing tumor growth ...
Yanxuan Guo, Yingge Lv, Shuyu Huang, Chang Liu, Yan Ouyang, Bei Lan, Chenghao Xuan   +6 more
wiley   +1 more source